# Contents

August 1, 2007  
Vol 13, No 15  
(Part 2 of 2)

<table>
<thead>
<tr>
<th>Program Faculty</th>
<th>i</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsorship and CME Credit</td>
<td>ii</td>
</tr>
<tr>
<td>CME Activity Assessment and Evaluation</td>
<td>iv</td>
</tr>
</tbody>
</table>

## Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference


## Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer

- Roman Perez-Soler ........................................................................................................ 4589s

## HKI-272 in Non–Small Cell Lung Cancer

- Kwok-Kin Wong ................................................................................................................ 4593s

## Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab

- Mark A. Socinski .............................................................................................................. 4597s

## Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?

- Daniel Morgensztern and Ramaswamy Govindan ............................................................ 4602s

## Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors

- Philip D. Bonomi, Lela Buckingham, and John Coon ...................................................... 4606s

## Bevacizumab in Non–Small Cell Lung Cancer

- Alan Sandler ....................................................................................................................... 4613s

## Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer

- Emer O. Hanrahan and John V. Heymach ........................................................................... 4617s

## Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer

- Gregory J. Riely and Vincent A. Miller ............................................................................. 4623s

## Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer

- Bruce E. Johnson, David Jackman, and Pasi A. Jänne ........................................................ 4628s

## Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations

- Julie E. Bauman, Keith D. Eaton, and Renato G. Martins ................................................ 4632s

## The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer

- Jeffrey A. Engelman ........................................................................................................... 4637s

## Enzastaurin, a Protein Kinase Cβ-Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer

- Roy S. Herbst, Yun Oh, Asavari Wagle, and Michael Lahn ................................................ 4641s

## Incorporating Bortezomib into the Treatment of Lung Cancer

- Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara .................. 4647s

## L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer

- Randeep Sangha and Charles Butts .................................................................................... 4652s